Live federal data · NADAC weekly · Part D CY24

Cariprazine Aripiprazole

Cariprazine vs Aripiprazole — $3.20B of combined CY2024 Part D plan spend across 2 molecules. Side-by-side data, every number traced to its CMS or FDA source.

Last updated 14 Jul 2026

NADAC: refreshed weeklyPart D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Atypical Antipsychotic

Cariprazine

Brand: Vraylar

First FDA approval: 2015-09-17

Atypical Antipsychotic

Aripiprazole

Brand: ABILIFY

First FDA approval: 2002-11-15

Lowest NADACAcquisition cost floor across all NDCs

$50.81Per unit

$0.098Per unit

Average NADACAcross all dosage forms and strengths

$50.87Up to $50.92

$62.46Up to $2860.98

Generic manufacturersActive ANDA holders — FDA Orange Book

00 total ANDAs filed

22108 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$1.75BFull year

$1.45BFull year

Part D claims (CY24)Total fills, all strengths

1.2M216K beneficiaries

6.2M1.3M beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$1,489Per claim, all NDCs

$233Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

308Substantial friction

1127Substantial friction

Step therapy appliedPlan-NDC pairs requiring step therapy

256Limited friction

372Limited friction

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

NoBrand-only

Yes22 manufacturers